GSK RoCCPORT Chronic Cough
This study is a multinational, multi-center, observational, prospective, cohort study of patients with refractory chronic cough/unexplained chronic cough (RCC/UCC) and patients without RCC/UCC using primary data collection.
Study phase: N/A
Study phase (if other): Observational
Basic eligibility criteria:
Please contact the study coordinator for additional eligibility information.
1. Age 21 years at study entry
2. Current or new patient in an outpatient respiratory/pulmonology, ENT, or allergy/immunology clinic being evaluated or treated for RCC/UCC
3. Willing and able to provide written informed consent to participate in the study in a manner approved by the IRB/IEC and local regulations
4. Willing to wear the cough monitor during the 4-week study period
5. Have cough lasting greater than 8 weeks prior to study entry Comparison Cohort participants must meet all the following criteria to be eligible for participation in the study: 1. Age ? 21 years at study entry
6. Current or new patient in an outpatient respiratory/pulmonology, ENT, or allergy/immunology clinic not being evaluated or treated for a respiratory disorder
7. Willing and able to provide written informed consent to participate in the study in a manner approved by the IRB/IEC and local regulations
8. Willing to wear the cough monitor during the 4-week study period
Primary disease category: Asthma & Lung
Secondary disease categories: Allergy & Immunology
Sponsor: GSK
Protocol number: 222179 RoCCPORT
Projected enrollment dates: June 2025 to December 2026
Official study title: A Prospective Cohort Study of Patients with Refractory or Unexplained Chronic Cough measuring Cough Variability and Burden on Patients’ Lives